Copertina

Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Hyungwoo Cho, Kihyun Kim, Sang Eun Yoon, Sung‐Hoon Jung, Je‐Jung Lee, Joon Ho Moon, Hee Jeong Cho, Ho Sup Lee, Ka‐Won Kang, Sung‐Yong Kim, Hyeon‐Seok Eom, Yeung‐Chul Mun, Young Hoon Park, Sung‐Soo Yoon, Young Rok Do, Won Sik Lee, Chang‐Ki Min, Dok Hyun Yoon
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	HemaSphere
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Prospective phase II study of allogeneic hematopoietic stem cell transplantation with targeted busulfan, fludarabine, and etoposide conditioning in pediatric acute lymphoblastic leukemia
di: Kyung Taek Hong, et al.
Pubblicazione: (2024)

European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
di: Niccolò Bolli, et al.
Pubblicazione: (2025)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
di: Cristina De Ramón, et al.
Pubblicazione: (2024)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
di: Ola Landgren, et al.
Pubblicazione: (2025)

Combining SKY92 gene expression profiling and FISH (according to R2‐ISS) defines ultra‐high‐risk Multiple Myeloma
di: Xiang Zhou, et al.
Pubblicazione: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Pubblicazione: (2025)

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
di: Niels W. C. J. van de Donk, et al.
Pubblicazione: (2025)

Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients
di: Maria Papatsirou, et al.
Pubblicazione: (2024)

High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
di: Andrea Manubens, et al.
Pubblicazione: (2025)

30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
di: Enrique M. Ocio, et al.
Pubblicazione: (2024)

Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
di: Kazimierz Groen, et al.
Pubblicazione: (2025)

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels
di: Wassilis S. C. Bruins, et al.
Pubblicazione: (2025)

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma
di: Juan‐Jose Garces, et al.
Pubblicazione: (2025)

Navigating the evolving management of smoldering multiple myeloma
di: M. Bakri Hammami, et al.
Pubblicazione: (2026)

High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
di: Veronica González‐Calle, et al.
Pubblicazione: (2024)

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial
di: Elias K. Mai, et al.
Pubblicazione: (2024)

Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies
di: Eirini Katodritou, et al.
Pubblicazione: (2025)

Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma
di: Zoltán Kellermayer, et al.
Pubblicazione: (2024)

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
di: Kazimierz Groen, et al.
Pubblicazione: (2024)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
di: Patrick Born, et al.
Pubblicazione: (2025)

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma
di: Larissa Haertle, et al.
Pubblicazione: (2024)

CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma
di: Johannes Steinhart, et al.
Pubblicazione: (2024)

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells
di: Romane Durand, et al.
Pubblicazione: (2024)

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
di: Wassilis S. C. Bruins, et al.
Pubblicazione: (2024)

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
di: Anna de Daniel, et al.
Pubblicazione: (2024)

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
di: Benjamin A. Derman, et al.
Pubblicazione: (2025)

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
di: Sonia Morè, et al.
Pubblicazione: (2025)

Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study
di: Axel André, et al.
Pubblicazione: (2024)

Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
di: Meral Beksac, et al.
Pubblicazione: (2026)

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
di: Prashant R. Tembhare, et al.
Pubblicazione: (2024)

Monocyte‐mediated metabolic rewiring via CD31‐CD38 interactions promotes growth and drug‐resistance in multiple myeloma
di: Ramin Raoof, et al.
Pubblicazione: (2026)

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
di: Michael H. Tomasson, et al.
Pubblicazione: (2024)

Correction to Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
Pubblicazione: (2025)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
di: Thomas C. Wiemers, et al.
Pubblicazione: (2026)

Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID‐19 pandemic: A population‐based, nation‐wide study
di: Tereza Faitová, et al.
Pubblicazione: (2024)

Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up
di: Francesco d'Amore, et al.
Pubblicazione: (2025)

Daratumumab‐based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case‐control study
di: Claudia Bellofiore, et al.
Pubblicazione: (2025)

Mitigation of atrial fibrillation‐related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG‐MPN bioregistry
di: Hyunyee Rosa Cho, et al.
Pubblicazione: (2025)

Autologous stem cell transplantation in NK/T‐cell lymphoma: Prognostic impact of EBV‐DNA in a multinational cohort—A study by the EBMT Lymphoma Working Party
di: Philipp Berning, et al.
Pubblicazione: (2025)

Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia
di: Bela Patel, et al.
Pubblicazione: (2024)